Aurinia Pharmaceuticals Inc. (AUPH)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Aurinia Pharmaceuticals Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Aurinia Pharmaceuticals Inc. (AUPH) has returned -7.08% so far this year and 84.33% over the past 12 months. Looking at the last ten years, AUPH has achieved an annualized return of 17.52%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.

Based on dividend-adjusted daily data since Sep 3, 2014, AUPH's average daily return is +0.15%, while the average monthly return is +3.26%. At this rate, your investment would double in approximately 1.8 years.

Historically, 51% of months were positive and 49% were negative. The best month was Dec 2019 with a return of +155.2%, while the worst month was Nov 2021 at -43.1%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.

On a daily basis, AUPH closed higher 47% of trading days. The best single day was Dec 5, 2019 with a return of +78.8%, while the worst single day was Aug 15, 2016 at -55.8%.

Aurinia Pharmaceuticals Inc. has an annualized alpha of 31.77%, beta of 0.89, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since September 04, 2014.

• This stock captured 133.51% of S&P 500 Index gains and 127.79% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AUPH ranks 89 for risk / return — in the top 89% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Aurinia Pharmaceuticals Inc. (AUPH) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Aurinia Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aurinia Pharmaceuticals Inc. was 87.58%, occurring on Dec 27, 2022. The portfolio has not yet recovered.

The current Aurinia Pharmaceuticals Inc. drawdown is 55.20%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Aurinia Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Aurinia Pharmaceuticals Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.